Scleroderma-Specific Autoantibodies in Early Systemic Sclerosis Prognostication is tenous in early scleroderma, especially in those with dcSSc. dcSSc has associated with substantial morbidity and disease-specific mortality. Analysis of an early SSc registry shows that anti-RNA https://t.co/Qvu2vSShcg

Obesity and Psoriatic Disease Obesity is a clinically important comorbidity in psoriasis (PsO) and psoriatic arthritis (PsA). Excess adiposity contributes to systemic inflammation and cardiometabolic risk and may adversely affect disease severity and response to some systemic https://t.co/WVIqfq8vEj

Gabapentin Use Rose as Restrictions Fell, Study Shows Gabapentin use jumped quickly in Michigan after the drug was removed from the state's controlled substance schedule in 2024, a cross-sectional study showed. https://t.co/xQ9MHqnNxB https://t.co/ipOWS4K61U

Retrospective review of 33 referred pts w/ Recurrent fever w/ MSK & skin Sxs, assessed by NGS. NLRP1 had FMF-like Dz; NLRP recurrent fevers w/ mucocutaneous; NLRP12 periodic fevers w/ MP/EN rash; NLRC4 episodic systemic inflammation GI Sxs & atypical skin rash https://t.co/Ll2V0Uzfio

FDA has approved baricitinib (Olumiant) for the treatment of pediatric patients 12 years of age and older with severe alopecia areata https://t.co/OTXXQvNruw https://t.co/xrg5ocWyjo

Prescribing New GLP-1-Based Therapies https://t.co/cpxyxBMZ8s https://t.co/yV8Jvkh2sk

🚨 Registration opens October 1! RheumNow Live 2027 returns January 30–31 for our 9th Annual CME Meeting. 📍 Dallas + Online 📅 January 30–31, 2027 🎓 High-impact CME. Expert faculty. Real-world rheumatology. The rheumatology meeting that sets the tone for the year ahead. https://t.co/1u27pab4Ee

Amgen announced topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep (CD40L antagonist fusion protein) in adult Sjögren's dz w/ positive ESSDAI results at wk 48 https://t.co/hBKIdOE9aR https://t.co/y3tXp5xwgC

Systematic review 14 studies assessed Lung ultrasound (LUS) (vs HRCT) to detect RA-ILD (using threshold of ≥ 5 B-lines) found sensitivity was 86.8% (95% CI 80.1–91.4), specificity 75.4% (95% CI 62.3–85.1), and AUC 0.890 https://t.co/GlNpsPBwtS https://t.co/I4mITEqBI6

Study of 119 Rheum pts on GLP-1 Rx (65% T2DM, 35% obesity; mean BMI 35). @ 12 mos wt loss −7.7 kg & 56% improved ≥1 BMI category. Signif decr in A1c, FBS, lipids, LDL, TG, ESR & CRP. GLP-1RAs useful cardiometabolic benefits https://t.co/fdNtvGu8Vb~ https://t.co/vM3Ukr9XUF

Do You Have to be Overweight for GLP-1s to Work? https://t.co/7IsksT3x45 https://t.co/DaF2Dgt5Xm

TNR: Obesity Treatment & Safety https://t.co/IG3dKVWV8e https://t.co/oO1bFQa8wy

Endocrine Society - State of Obesity Science and Management The Endocrine Society has published a scientific statement reframing obesity as a heterogeneous, chronically dysregulated fat-mass disorder, whose biology is being effectively tested by GLP-1/GIP receptor agonists. Is https://t.co/FHHTNcp9gL

Lifestyle and Incretin Therapy Advice for Rheumatologists As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective reframes lifestyle counseling as an adjunct to pharmacotherapy - a https://t.co/ltPdGEgQ60